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Summary
 
Bystander activation, i.e., activation of T cells specific for an antigen 
 
X
 
 during an immune re-
sponse against antigen 
 
Y
 
 may occur during viral infections. However, the low frequency of by-
stander-activated T cells has rendered it difficult to define the mechanisms and possible in vivo
relevance of this nonspecific activation. This study uses transgenic mice expressing a major his-
tocompatibility complex class I–restricted TCR specific for glycoprotein peptide 33-41 of lym-
phocytic choriomeningitis virus (LCMV) to overcome this limitation. CD8
 
1
 
 T cells from spe-
cific pathogen-free maintained, unimmunized “naive” TCR transgenic mice can differentiate
into LCMV-specific cytolytic effector CTL during infections with vaccinia virus or 
 
Listeria
monocytogenes
 
 in vivo or mixed lymphocyte culture in vitro. We show that in these model situ-
ations (
 
a
 
) nonspecifically activated CTL are able to confer antiviral protection in vivo, (
 
b
 
) by-
stander activation is largely independent of the expression of a second T cell receptor of differ-
ent specificity, (
 
c
 
) bystander activation is not mediated by a broadly cross-reactive TCR, but
rather by cytokines, (
 
d
 
) bystander activation can be mediated by cytokines such as IL-2, but not
 
a
 
/
 
b
 
-IFN in vitro; (
 
e
 
) bystander activation is, overall, a rare event, occuring in vivo in roughly
1 in 200 of the LCMV-specific CTL during infection of TCR transgenic mice with vaccinia
virus; (
 
f
 
) bystander activation does not have a significant functional impact on nontransgenic
CTL memory under the conditions tested; and (
 
g
 
) even in the TCR transgenic situation,
where unphysiologically high numbers of T cells of a single specificity are present, bystander
activation is not sufficient to cause clinically manifest autoimmune disease in a transgenic
mouse model of diabetes. We conclude that although bystander activation via cytokines may
generate cytolytically active CTL from naive precursors, quantitative considerations suggest
that this is usually not of major biological consequence.
 
S
 
pecificity is one of the hallmarks of the adaptive im-
mune system. For CTL, specific activation requires the
interaction of the TCR with its nominal peptide bound to
MHC class I molecules. The questions of whether, how, and
to what extent CTL can also be nonspecifically activated in
the absence of this cognate interaction are of obvious im-
portance; nonspecific activation of potentially self-reactive
T cells during immune responses to foreign antigens may trig-
ger autoimmune diseases. In addition, reactivation of primed
T cells by heterologous viruses or cytokines has been pos-
tulated to contribute to maintenance of immunological mem-
ory (1–5).
Unspecific polyclonal stimulation of alloreactive CTL
has been described to occur during viral infections (6–8) in
mice and in humans (9–11). The high precursor frequency
of alloreactive CTL clones allows detection of this nonspe-
cific stimulation in a cytotoxicity assay. Also, nonspecific
activation of antiviral memory CTL, displaying an interme-
diate precursor frequency, has been demonstrated, mainly
using limiting dilution assays (2, 3). In contrast, the fre-
quency of naive precursor CTL against viral or self antigens
is comparatively low. Whether these cells may be nonspe-
cifically activated has, therefore, been difficult to study in
functional assays.
The mechanisms postulated to be involved in nonspe-
cific T cell activation are poorly characterized; they include
the following. (
 
a
 
) Cross-reactivity at the level of the TCR,
which recognizes MHC molecules presenting the nominal
peptide, but could also bind to a nonnominal peptide with
sufficient avidity for the T cell to be activated. Several ex-
amples for this “molecular mimicry” have been postulated
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and presented (12). (
 
b
 
) Activation of a given T cell by a vi-
rus-specific TCR, which could lead to effector function of
this T cell via a second TCR of different (e.g., self) speci-
ficity (13). It has been shown that allelic exclusion of the
 
a
 
 chain of the T cell receptor is incomplete (14, 15), and
T cells carrying two different TCRs have been demon-
strated in mice (16, 17) as well as in humans (18). (
 
c
 
) “By-
stander activation” via cytokines secreted by antigen-respon-
sive cells such as type I IFN (5) or combinations of other
cytokines (4) which could act independently of the TCR.
When discussing the biological effects of this nonspecific
T cell activation, a strict definition of “activation” is indispen-
sable. Whereas proliferation or upregulation of certain sur-
face markers are measurable signs of activation, the extent
these phenomena reflect in vivo effector function varies
between experimental systems. In the lymphocytic chori-
omeningitis virus (LCMV)
 
1
 
 model used in this study, CTL-
mediated antiviral effector function is almost exclusively
mediated by contact-dependent perforin-mediated cyto-
toxicity. Within this system, the question of whether by-
stander activation is of biological significance in vivo, can
therefore be studied by assessing whether nonspecific acti-
vation can induce cytolytically active effector CTL, which
can mediate antiviral protection, immunopathology, or au-
toimmunity.
In this study, we analyzed the mechanisms of how TCR
transgenic CD8
 
1
 
 cytotoxic T cells specific for an LCMV-
derived peptide presented by H-2D
 
b
 
 may differentiate into
LCMV-specific cytolytic effector cells during infections with
unrelated pathogens in vivo or mixed lymphocyte cultures
in vitro. The high precursor frequency of CTL of a defined
specificity in these transgenic mice allowed us to address
the following questions: (
 
a
 
) Are these “bystander” CTL pro-
tective against LCMV infection in vivo? (
 
b
 
) Which mecha-
nisms are responsible for the nonspecific activation?, (
 
c
 
) How
many CTL of a defined specificity are activated?, (
 
d
 
) Does
bystander activation have a functional impact on CTL mem-
ory in nontransgenic mice?, and (
 
e
 
) Can bystander CTL
cause autoimmune disease in a corresponding transgenic
mouse model of diabetes mellitus?
 
Materials and Methods
 
Mice.
 
C57BL/6 and BALB/c mice were obtained from the
Institut für Labortierkunde (University of Zürich, Zürich, Swit-
zerland). The transgenic mice expressing a V
 
a
 
2/V
 
b
 
8.2 T cell recep-
tor specific for amino acids 33–41 of the LCMV glycoprotein 1 in
association with H-2 D
 
b
 
 have been described previously (19). For
this study, mice of the line 327 (expressing the transgenic TCR
on 85–95% of all CD8
 
1
 
 T cells) and for some indicated experi-
ments of line 318 (expressing the transgenic TCR on 50–60% of
CD8
 
1
 
 T cells) were used. TCR transgenic mice (line 318) crossed
onto a RAG-2–deficient background (referred to as TCR 
 
3
 
RAG 
 
2
 
/
 
2
 
 mice; 20) were bred locally (breeding pairs provided
by Dr. Pamela Ohashi, Ontario Cancer Institute, Toronto, Can-
ada). TCR transgenic mice (line 318) deficient in functional ex-
pression of the 
 
a
 
/
 
b
 
-IFN receptor were generated by crossing
with the appropriate gene targeted mice (21). TCR transgenic
mice (line 327) expressing the LCMV glycoprotein under control
of the rat insulin promoter (RIP-gp/TCR mice) have been de-
scribed previously (22). All mice were kept under specific patho-
gen-free conditions, which included a test every 6 mo for the ab-
sence of 9 specified viruses, 21 bacteria, and 13 other pathogens
such as fungi and protozoa. The mice are considered “naive” if
they were not deliberately immunized.
 
Viruses and Bacteria.
 
Vaccinia virus WR was grown on BSC-
40 cells. Recombinant vaccinia virus expressing the LCMV gly-
coprotein (vacc G2) was obtained from B.H. Bishop (University of
Oxford, Oxford, UK) and also grown on BSC 40 cells. LCMV-
WE was originally obtained from F. Lehmann-Grube (Heinrich-
Pette-Institut für Experimentelle Virologie und Immunologie der
Universitàt Hamburg, Hamburg, Germany) and was propagated
on L 929 fibroblast cells. A seed of 
 
Listeria monocytogenes
 
 was origi-
nally obtained from R.V. Blanden (Australian National University,
Canberra, Australia) and was maintained in a virulent state by pas-
sage in mice. A frozen (
 
2
 
70
 
8
 
C) stock culture was used to prepare
a fresh 12–16 h culture in trypticase soy broth (BBL Microbiol-
ogy Systems, Cockeysville, MD) for each experiment. The infec-
tive dose used was aimed at being about 3 
 
3
 
 10
 
3
 
 bacteria per
mouse and was assessed retrospectively by plating each inoculum.
 
Cytotoxicity Assays.
 
6 d after vaccinia virus infection or 5 d af-
ter infection with 
 
Listeria monocytogenes
 
, effector cell suspensions
were prepared from spleens of infected mice. For some experiments,
mice were injected with 200 
 
m
 
g poly (IC) (Fluka, Chemie Ab,
Buchs, Switzerland) intravenously 3 and/or 1 d before the cyto-
toxicity assay. MC57G (H-2
 
b
 
) target cells were pulsed with
LCMV glycoprotein peptide 33-41 (gp33; 10
 
2
 
6
 
 M) for 2 h, in-
fected with LCMV-WE for 48 h or infected with vaccinia virus
WR at a multiplicity of infection of 3 for 2.5 h; uninfected cells
served as controls. 5–6 h 
 
51
 
Cr-release assays were performed ac-
cording to standard protocols (23); for overnight (15 h) assays,
EL-4 cells unlabeled or pulsed with gp33 were used as target cells.
For the cold target competition assays, effector cells and 
 
51
 
Cr-labeled
(“hot”) LCMV-WE–infected MC57G target cells were incu-
bated at a fixed effector/target ratio and nonradiolabeled (“cold”)
target cells were added at the indicated cold/hot target ratio.
For in vitro MLC, 5 
 
3
 
 10
 
6
 
 responder spleen cells (H-2
 
b
 
) were
cultured in 24-well plates with 5 
 
3
 
 10
 
6
 
 irradiated (2,000 rad) al-
logeneic spleen cells (H-2
 
d
 
). Cultures were set up in a total vol-
ume of 2 ml IMDM 10% FCS. The ability of cytokines to induce
cytolytic effector CTL in the absence of stimulator cells was tested
by culturing responder spleen cells from TCR 
 
3
 
 RAG 
 
2
 
/
 
2
 
 mice
in medium supplied with 500 U/ml of recombinant human IL-2
(Hoffmann-La Roche, Nutley, NJ) on days 1 and 4. Alternatively,
the cells were incubated in supernatant of C57BL/6 (H-2
 
b
 
) 
 
3
 
BALB/c (H-2
 
d
 
) MLC cultures which had been set up 1 d previ-
ously, and medium was supplied daily from the parallel MLC. Af-
ter 5 d, the cultures were harvested in 500 
 
m
 
l MEM 2% FCS and
100 
 
m
 
l of a 1-, 3-, 9-, and 27-fold dilution (referred to as dilution
of culture) was added to 10
 
4
 
 
 
51
 
Cr-labeled target cells. MC57G
(H-2
 
b
 
) target cells were used either unlabeled or pulsed with
LCMV peptide gp33. To test for anti–H-2
 
d
 
 alloreactivity, P815
cells were used. Specific 
 
51
 
Cr-release was determined after 5 h in-
cubation.
Antiviral effector function of activated CTL in vivo was mea-
sured in adoptive transfer experiments. For this, recipient C57BL/6
mice were infected with 10
 
4
 
 PFU LCMV-WE intravenously and
10 h later, spleen cells from various naive and acutely infected do-
 
1
 
Abbreviations used in this paper:
 
 gp33, glycoprotein 33-41; LCMV, lym-
phocytic choriomeningitis virus; RIP, rat insulin promotor; SPF, specific
pathogen-free. 
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nor mice were injected intravenously in a volume of 500 
 
m
 
l bal-
anced salt solution. 18 h after transfer, virus titers were deter-
mined in the spleen using a virus plaque assay on MC57G cells as
described previously (24).
 
Induction of Diabetes.
 
RIP-gp/TCR double-transgenic mice
were infected with 2 
 
3
 
 10
 
6
 
 PFU of vaccinia WR or recombinant
vaccinia G2. Blood glucose levels were then determined every 3 d
by using a haemo-glucotest kit and were quantitated with reflolux
II (Boehringer Mannheim, GmbH, Mannheim, Germany). Ani-
mals were considered diabetic when blood glucose levels persisted
above 14 mM for at least 3 d. Immunohistochemical analysis of
pancreata with antibodies directed against CD4 and CD8 was
performed as descibed previously (22). The islets of Langerhans
were considered infiltrated if more than 10 positive lymphocytes
were detected per islet section.
 
Results
 
Activation of Naive LCMV-specific Cytotoxic T Cells by Un-
related Infections In Vivo or by Allo-antigens In Vitro.
 
The ques-
tion of whether cytotoxic T cells specific for a defined viral
antigen can be activated by nonspecific antigens in vivo
was analyzed in a mouse transgenic for the V
 
a
 
2/V
 
b
 
8 TCR
specific for the gp33 of LCMV (19). This mouse expresses
the transgenic TCR on 90% of all CD8
 
1
 
 CTL rendering
rare bystander activation events in this CTL population
more easily detectable in functional assays. Naive (as de-
fined in Material and Methods) TCR transgenic and
C57BL/6 mice were infected with 5 
 
3
 
 10
 
6
 
 PFU vaccinia
WR virus, which is unrelated to LCMV. 6 d later, cyto-
toxic activity against target cells infected with vaccinia WR
(Fig. 1 
 
a
 
) or pulsed with LCMV peptide gp33 (Fig. 1 
 
b
 
) was
tested in a 
 
51
 
Cr-release assay. Whereas spleen cells from both
mouse strains showed effective lysis of vaccinia infected tar-
get cells, cytotoxic activity against LCMV peptide–loaded
target cells could only be found in spleens of vaccinia
WR–infected TCR transgenic but not in C57BL/6 mice,
the latter exhibiting a low LCMV-specific CTL precursor
frequency (Fig. 1 
 
b
 
). Furthermore, activation of LCMV-
specific CTL could be demonstrated after infection of TCR
transgenic mice with 
 
Listeria monocytogenes
 
, a facultative in-
tracellular bacterium (Fig. 1, 
 
d
 
 and 
 
e
 
). Finally, when spleen
cells from TCR transgenic mice (H-2
 
b
 
) were stimulated with
allogeneic spleen cells from BALB/c mice (H-2
 
d
 
) in an
MLC, significant LCMV-specific cytotoxicity was gener-
ated (Fig. 1 
 
g
 
). These data, obtained similarly with mice kept
under conventional or under SPF conditions, show that na-
ive virus-specific precursor CTL can be activated by non-
specific antigens in vitro and in vivo. In TCR transgenic
mice, this bystander activation generates strong LCMV-
specific cytotoxic activity, which allows further analysis of
the mechanisms involved. As will be shown later, mono-
clonal TCR 
 
3
 
 RAG 
 
2
 
/
 
2
 
 mice could not be used in the
in vivo experiments because the monospecific repertoire
renders these mice incompetent to control and eliminate
infections with vaccinia virus or 
 
Listeria
 
 (data not shown).
 
Antiviral Protection In Vivo Induced by Bystander Activation
of Naive Cytotoxic T Cells.
 
To study whether LCMV-spe-
cific CTL activated by the unrelated vaccinia virus infection
are functional in vivo, we tested their ability to confer anti-
viral protection upon adoptive transfer. This indirect ap-
proach was chosen instead of direct LCMV challenge of
the vaccinia infected mice, because LCMV does not reach
 
Figure 1.
 
Activation of LCMV-specific TCR transgenic T cells by un-
related pathogens in vivo and by allo-antigens in vitro. (
 
a–e
 
) C57BL/6
mice (
 
closed circles
 
) and TCR transgenic mice from line 327 (
 
open circles
 
)
were infected intravenously with 2 
 
3
 
 10
 
6
 
 PFU vaccinia WR (
 
a–c
 
) or with
5 
 
3
 
 10
 
3
 
 CFU 
 
Listeria monocytogenes
 
 (
 
d 
 
and
 
 e
 
). 6 and 5 d later, respectively,
splenic cytotoxic activities were tested on MC57G target cells infected
with vaccinia WR (
 
a
 
), labeled with the LCMV peptide gp33 (
 
b and d), or
left unlabeled (c and e). (f–h) Spleen cells from C57BL/6 (closed circles) and
TCR trangenic mice of line 327 (both H-2b; open circles) were stimulated
in a mixed lymphocyte reaction on irradiated spleen cells from BALB/c
mice (H-2d). 5 d later, cytotoxic activity of the MLC cultures was tested
on P815 (H-2d) (f), MC57G (g), or MC57G (H-2b) (h) cells pulsed with
LCMV gp33. Spontaneous release in all assays was ,24%. All experi-
ments were performed at least two times.1244 Bystander Activation of Cytotoxic T Cells
significant titers even in naive TCR transgenic mice. A group
of C57BL/6 mice was infected with 104 PFU LCMV-WE.
10 h later, these preinfected, but otherwise unmanipulated,
recipient mice were transfused with various spleen cell
populations to compare their ability to control virus repli-
cation in vivo. Donor spleen cell populations from the fol-
lowing groups of mice were used (Fig. 2): 1, naive C57BL/6
mice; 2, C57BL/6 mice infected with 2 3 106 PFU vac-
cinia WR 6 d previously; 3, naive TCR transgenic mice
(negative controls); 4, TCR transgenic mice infected with
2 3 106 PFU vaccinia WR 6 d previously (experimental
group); and 5 and 6, C57BL/6 mice infected with 200
PFU LCMV-WE 8 d before transfer (positive control). 20 h
after transfer, the recipent mice were killed and virus titers
were determined in the spleens. Fig. 2 shows that within
20 h, the transgenic CTL activated by vaccinia virus had al-
most completely controlled the infection with LCMV,
while spleen cells from naive transgenic or vaccinia primed
nontransgenic mice had no effect. These data demonstrate
that in TCR transgenic mice bystander activation may in-
duce CTL which are antivirally protective in vivo.
Bystander Activation of LCMV-specific Memory CTL Is of
Little Functional Consequence. Whereas the TCR transgenic
mice have an extremely high (1021) LCMV-specific CTLp
frequency and naive C57BL/6 mice a low (1026), LCMV-
infected memory C57BL/6 mice display intermediate (1023–
1024) frequencies. Bystander proliferation and modulation
of memory CTLp has previously been described after in-
fection with heterologous viruses (2, 3) or injection of poly
IC, a strong inducer of type I IFN (5). To test whether
these nonspecific stimuli may also have functional conse-
quences for CTL memory, we compared the cytolytic ef-
fector function of memory CTL in the presence or absence
of these stimuli. Infection with 2 3 106 PFU of the heter-
ologous vaccinia virus for 6 d (Fig. 3 a) did not improve cy-
tolytic effector function of memory CTL as measured ex
vivo in a 5 h and an overnight CTL assay, which permits
assessment of even relatively minor cytotoxic activity. Sim-
ilar results were obtained when 200 mg poly IC was in-
jected 3 and 1 d before the assay (Fig. 3 c) The antiviral
protective capacity of memory spleen cells 50 d after prim-
ing with LCMV upon adoptive transfer into preinfected
recipients was small, but reproducible (Fig. 3 b, group 2).
However, this antiviral protection was also not improved if
the LCMV memory mice had been boosted with 2 3 106
PFU vaccinia 6 d before the transfer (Fig. 3 b, group 3).
Quantitative Analysis of Bystander Activation of CTL In
Vivo. To put the results obtained in a TCR transgenic
mouse into a quantitative perspective, we addressed the
question of how many LCMV-specific precursors needed
to be present for bystander activation to become detectable
in a functional CTL assay. TCR transgenic mice from line
327 (90% of CD81 T cells express the transgenic TCR), from
line 318 (50% of CD81 T cells express the transgenic TCR),
and C57BL/6 mice, the latter had been adoptively trans-
fused with 108 or 107 spleen cells from mice of line 318 1 d
previously (z17 and 4%, respectively, of CD81 T cells ex-
pressed the transgenic TCR as determined by blood
FACSÒ analysis; data not shown), were infected with vac-
cinia WR. 6 d later, LCMV-specific cytotoxic activity was
tested in an overnight 51Cr-release assay. Fig. 4 a shows that
.4% of the spleen cells (corresponding to a CTLp fre-
quency of .1022) had to express a defined TCR for this
experimental protocol to detect activation of CTL in vivo
by a heterologous virus infection in a subsequent cytotox-
icity assay. This readily explains the fact that in using func-
tional assays, bystander activation was not detectable in non-
transgenic mice. Although in a memory situation CTL may
differ in their sensitivity to nonspecific (re-) activation stim-
uli (25, 26), this important quantitative consideration may
help to explain why protective bystander activation could
also not be observed in memory mice.
An approximate estimation of how many of the LCMV-
specific naive precursor CTL actually differentiated into
cytolytic effector CTL during the infection with the unre-
lated vaccinia virus was obtained as follows. The LCMV-
specific cytolytic activity in vitro and the antiviral protec-
tive capacity in vivo of TCR transgenic spleen cells primed
nonspecifically with vaccinia virus was compared to that of
C57BL/6 spleen cells primed specifically with LCMV. The
indirect comparison with C57BL/6 mice was chosen be-
cause in the acute phase of LCMV infection (day 8) of these
mice, most LCMV-specific CTLp have differentiated into
cytolytically active effector CTL; this extent can not reli-
ably be achieved by LCMV infection of TCR transgenic
mice, rendering quantitative comparisons difficult. In an
overnight CTL assay, 50% lysis of LCMV gp33-labeled tar-
get cells required an E/T ratio of z14:1 in the vaccinia-
Figure 2. Antiviral protection in vivo induced by bystander activation
of cytotoxic T cells. C57BL/6 mice were infected with 104 PFU LCMV-
WE intravenously, and 10 h after infection, adoptively transfused with the
indicated numbers of spleen cells from naive (groups 1 and 3), vaccinia
infected (groups 2 and 4), or LCMV-infected (groups 5 and 6) C57BL/6
or TCR transgenic mice (line 327). 18 h after adoptive transfer, virus ti-
ters were determined in the spleens of recipient mice. One of three simi-
lar experiments is shown.1245 Ehl et al.
primed TCR transgenic spleen and about 0.7:1 in the LCMV-
primed C57BL/6 spleen, corresponding to a roughly 20-fold
relative difference in cytotoxic activity (Fig. 4 b). A similar
number was obtained when the antiviral effector function
in vivo was compared. About 25 times more, i.e., 5 3 107
spleen cells from transgenic mice infected with the nonspe-
cific virus (Fig. 2, group 4) were needed to reach the same
antiviral protection as with 2 3 106 spleen cells from C57BL/6
mice activated by the appropriate virus (group 5). Thus, a
spleen from TCR transgenic mice infected with vaccinia
virus generates about 20-fold less LCMV-specific cytotoxic
activity than a spleen from C57BL/6 mice acutely infected
with LCMV. This difference in cytotoxic activity based on
total spleen cell numbers increases even more if we con-
sider that on the day of the assay, the number of LCMV-
specific CTL differs by a factor of z10 between the two
spleen cell populations; at the peak of the anti-LCMV re-
sponse in the C57BL/6 spleen, 5–10% of CTL are LCMV-
specific (27), whereas in the TCR transgenic spleen, 90%
of CTL are specific for LCMV. On a per cell basis, it can
therefore be calculated, that z20 3 10 5 200-fold less
LCMV-specific cytotoxic activity was generated through
Figure 3. Functional analysis of bystander-activated LCMV-specific memory CTL with no evidence of enhancement of cytolytic CTL activity assessed
in vitro and in vivo. (a) Primary ex vivo cytolytic activity of C57BL/6 mice immunized with 200 PFU LCMV-WE 50 d previously (open circles) or im-
munized with LCMV and boosted with 2 3 106 PFU vaccinia WR 6 d before the assay (closed circles) was analyzed in a 5-h and 15-h 51Cr-release assay on
EL-4 target cells labeled with LCMV gp33. Spontaneous release was 28%. (b) C57BL/6 mice were infected with 104 PFU LCMV-WE intravenously,
and 10 h after infection, adoptively transfused with the indicated numbers of spleen cells from naive (group 1), LCMV infected 50 d previously (group 2),
LCMV infected and boosted with vaccinia virus 6 d before the assay (group 3), or acutely LCMV infected (group 4) C57BL/6 mice. 18 h after adoptive
transfer, virus titers were determined in the spleens of recipient mice. (c) Primary ex vivo cytolytic activity of C57BL/6 mice immunized with 200 PFU
LCMV-WE 150 d previously (open circles) or immunized with LCMV and injected with 200 mg poly IC 3 and 1 d before the assay (closed circles) was ana-
lyzed in a 15-h 51Cr-release assay on EL-4 target cells labeled with LCMV gp33. Spontaneous release was 28%.
Figure 4. Quantitative analysis
of vaccinia virus–induced LCMV-
specific TCR transgenic CTL.
(a) TCR transgenic mice from line
327 (closed circles), line 318 (closed
triangles), as well as C57BL/6
mice adoptively transfused with
108 ( closed squares) or 2 3 107
(open squares) spleen cells from
mice of line 318 were infected
with 2 3 106 PFU vaccinia WR.
6 d later, LCMV-specific splenic
cytotoxicity was assessed in a 15-h
51Cr-release assay on EL-4 target
cells pulsed with LCMV gp33 or
unlabeled. Spontaneous release
was 29%. One of two similar ex-
periments is shown. (b) C57BL/6
mice (closed circles) were infected with 200 PFU LCMV-WE and TCR transgenic mice from line 327 (open circles) with 2 3 106 PFU vaccinia WR. 8 and
6 d after infection, respectively, splenic cytotoxic activity was tested in a 15-h 51Cr-release assay on EL-4 target cells pulsed with LCMV gp33. Spontane-
ous release was 31%. One of two similar experiments is shown.1246 Bystander Activation of Cytotoxic T Cells
bystander activation than after infection with the appropri-
ate LCM virus. Within the limits of the indirect approach,
this suggests that overall z1 in 200 LCMV-specific CTL
differentiated into a cytolytic effector CTL during the in-
fection of TCR transgenic mice with vaccinia virus.
Bystander Activation of CTL Occurs in the Absence of a Sec-
ond TCR with Different Specificity and Is Likely to Be Mediated
by Cytokines. How can LCMV-specific transgenic CTL
be activated during an immune response to vaccinia virus?
A possible explanation would be the expression of a second
TCR specific for vaccinia virus by some of the LCMV-
specific CTL. FACSÒ analysis revealed that in naive TCR
transgenic mice, z1.8% of the CD81 T cells using the
transgenic Va2 chain expressed an additional Va3 or Va8
chain (data not shown). However, the limited range of Va-
specific antibodies available makes a more precise determi-
nation of the number of dual receptor T cells difficult and
the specificities conferred by a second a chain could not be
determined. We therefore chose cold target competition as
a functional assay to check for dual receptor T cells. We
reasoned that if lysis of 51Cr-labeled LCMV-infected target
cells was mediated by CTL carrying two TCRs (one spe-
cific for vaccinia and one specific for LCMV), it should be
possible to inhibit LCMV-specific lysis by adding an excess
of nonlabeled (cold) targets infected with LCMV and with
vaccinia virus, respectively. Fig. 5 a shows, that significant
inhibition was only achieved with LCMV-infected cold tar-
gets, whereas inhibition by cold vaccinia-infected target cells
did not exceed competition by cold uninfected MC57G cells.
Similar results were obtained when cold target competition
assays were performed with LCMV-specific effector cells gen-
erated in mixed lymphocyte cultures (Fig. 5 b).
To further dissect the mechanism of bystander activa-
tion, we used TCR transgenic mice crossed into a RAG2-
deficient background (TCR 3 RAG 2/2 mice). These
mice are unable to rearrange and express endogenous (non-
transgenic) TCR a or b chains, and therefore have only
T cells of a single specificity. This renders these mice in-
competent to control and eliminate infection with vaccinia
virus (data not shown). Since these mice have a Sv129 ge-
netic background and have not been sufficiently back-
crossed to C57BL/6, minor histocompatibility differences
did not allow the study of these cells after adoptive transfer
into immunocompetent C57BL/6 mice due to cell rejec-
tion. Therefore, we were only able to study nonspecific ac-
tivation of CTL from these mice in vitro. When stimulated
with irradiated BALB/c spleen cells, responder spleen cells
from TCR 3 RAG 2/2 mice neither generated allospe-
cific (Fig. 6 a) nor LCMV-specific cytotoxicity (Fig. 6 b)
above background. This indicates that the LCMV-specific
transgenic TCR does not cross-react with allogeneic H-2d
MHC antigen. However, when C57BL/6 spleen cells were
added to the culture at a TCR 3 RAG 2/2:B6 ratio of
10:1 (corresponding to the ratio of transgenic to endoge-
nous CD81 T cells in the TCR transgenic mice from line
327), the cultures showed both allo- and LCMV-specific
cytotoxic activity similar to cultures of TCR transgenic
spleen cells (Fig. 6, a–c). In the context of the experiments
summarized above, these data suggested that (a) bystander
activation in our experimental system occurs in the absence
of a second T cell receptor, (b) it is unlikely to be mediated
by a cross-reactive TCR, and (c) that the presence of cells di-
rectly responsive to the activating antigen is necessary for by-
stander activation, presumably via the secretion of cytokines.
The role of cytokines in nonspecific CTL activation was
further addressed as follows. Spleen cells from TCR 3
RAG 2/2 mice were cultured in the absence of stimula-
tor cells in medium obtained from an MLC using BALB/c
(H-2d) stimulators and C57BL/6 (H-2b) responders, which
had been set up 1 d previously. The medium of the TCR 3
RAG 2/2 culture was then daily exchanged with me-
dium of the parallel MLC. Alternatively, spleen cells from
Figure 5. LCMV-specific cy-
totoxicity generated by vaccinia
infection of TCR transgenic
mice cannot be blocked by vac-
cinia virus–infected target cells.
(a) TCR transgenic mice (line
327) were infected with 2 3 106
PFU vaccinia WR, and 6 d later,
splenic cytotoxic activity was
tested on 51Cr-labeled “hot”
MC57G cells infected with
LCMV-WE at a fixed effector/
target ratio of 100:1. Nonradio-
labeled “cold” MC57G cells un-
infected (closed bars), or infected
with LCMV-WE (open bars) or
with vaccinia WR (hatched bars)
were added at the indicated hot/
cold target ratio. (b) Spleen cells
from TCR transgenic mice (line
327; H-2b) were stimulated in an
MLC with irradiated BALB/c (H-2d) spleen cells for 5 d and used as effectors in a cold target competition assay as outlined above. MC57G cells (H-2b),
either uninfected (closed bars), or infected with LCMV-WE (open bars) or P815 (H-2d) cells (hatched bars) were used as cold targets. Spontaneous release
was ,23% in both assays. Each experiment was repeated three times.1247 Ehl et al.
TCR 3 RAG 2/2 mice were cultured in medium sup-
plied with 500 U/ml of recombinant human IL-2. After 5 d
of culture, cytotoxic activity against target cells labeled with
LCMV peptide gp33 was determined. Fig. 6, d–f shows that
supernatant of an allo-specific MLC or high concentrations
of IL-2 alone were sufficient for the nonspecific bystander
activation of LCMV-specific CTL.
Type I interferons have recently been implicated in “by-
stander proliferation” of memory CTL (5). To test whether
these cytokines are also involved in bystander activation of
naive CTL, we performed an MLC using spleen cells from
TCR transgenic mice crossed into an a/b interferon re-
ceptor–deficient background. Spleen cells from these mice
generated LCMV-specific cytotoxicity similar to littermate
controls (Fig. 7, a–c), suggesting that the nonspecific activa-
tion of naive CTL does not require type I interferons. Also,
the injection of poly IC, a strong inducer of type I interfer-
ons 3 and/or 1 d before the cytotoxicity assay, did not lead
to generation of LCMV-specific cytotoxicity, although sig-
nificant lysis of NK-sensitive YAC-1 targets was observed
(Fig. 7, d–f).
Bystander Activation of CTL Specific for a Self-Antigen Is Not
Sufficient to Cause Autoimmune Disease in a Transgenic Mouse
Model of Diabetes Mellitus. The important question of whether
bystander activation of CTL specific for a self-antigen may
cause autoimmune disease, was addressed in RIP-gp mice
(22). Autoimmune diabetes in RIP-gp mice can be induced
by infection with LCMV in the absence of an LCMV-spe-
cific TCR transgene (22). The introduction of this second
transgene amplifies the LCMV-specific CTLp z10,000-
fold, thereby significantly increasing the sensitivity of the
model (28). We infected such double transgenic (RIP-gp/
TCR mice) with vaccinia virus WR and monitored the
mice for development of diabetes by monitoring blood
glucose; in parallel, immunohistological examination eval-
uated local inflammation and lymphocytic infiltrations of
islets of the pancreas. All of the 10 mice observed from 6 to
60 d and 5 additional mice observed for 120 d after virus
infection remained normoglycemic even though primary
LCMV-specific cytotoxicity could readily be demonstrated
in these mice (data not shown, but similar to Fig. 1). The
histological examination revealed that <50% of the islets
showed infiltration by CD41 and CD81 lymphocytes (Ta-
ble 1). This demonstrates that bystander activation in these
Figure 6. Nonspecific activation of TCR transgenic LCMV-specific
CTL during a mixed lymphocyte reaction is mediated by cytokines and
not a cross-reactive TCR. (a–c) Spleen cells from C57BL/6 (open circles),
TCR transgenic line 327 (closed circles), TCR 3 RAG 2/2 mice (closed
circles), and spleen cells from TCR 3 RAG 2/2 mice supplemented
with 10% C57BL/6 (closed triangles) spleen cells (all H-2b) were used as re-
sponder cells in a mixed lymphocyte reaction on BALB/c (H-2d) stimula-
tor cells. (d–f) Spleen cells from TCR 3 RAG 2/2 mice were cultured
in the absence of stimulator cells either in supernatant of C57BL/6 versus
BALB/c MLC (closed triangles) or in medium supplemented with 500 U/ml
of IL-2 on days 1 and 4 of culture (closed circles). 51Cr-labeled P815 cells
(H-2d) (a, c), or EL-4 cells (H-2b) labeled with gp33 (b, d) or unlabeled (c, f )
were used as target cells.
Figure 7. No role for a/b-IFN in bystander activation of naive LCMV-
specific TCR transgenic CTL. (a–c) Spleen cells from TCR transgenic mice
(line 318) lacking the receptor for a/b-IFN (open circles) and heterozygous
littermates (closed circles) (both H-2b) were used as responder cells in a
mixed lymphocyte reaction on BALB/c (H-2d) stimulators. After 5 d of
culture, cytotoxic activity was tested on MC57G (H-2b) target cells either
unlabeled (c) or labeled with LCMV gp33 (b) and on P815 (H-2d) cells
(a). Spontaneous release was ,25%. One of two similar experiments is
shown. (d–f) TCR transgenic mice (line 327) were injected with 200 mg
poly(IC) intravenously 1 d (open circles), or 1 and 3 d (closed circles) before
testing splenic cytotoxic activity on NK-sensitive YAC-1 target cells (d),
MC57G target cells pulsed with LCMV gp33 (e), or unlabeled (f ). Spon-
taneous release was ,23%.1248 Bystander Activation of Cytotoxic T Cells
mice generated effector CTL that were indistinguishable from
CTL activated by their nominal antigen in their ability to
lyse target cells and to home to inflammatory lesions in vivo.
Nevertheless, the induction of a limited number of CTL
leading to infiltration of less than half of the pancreatic islets
appeared to be insufficient to cause clinically manifest dia-
betes mellitus. In contrast and as previously shown (22), in-
fection of RIPgp/TCR mice with a vaccinia recombinant
virus expressing the LCMV glycoprotein leading to activa-
tion of the CTL with their nominal antigen, induced dia-
betes and infiltration of .90% of the islets within 5–10 d
after infection (Table 1).
Discussion
This study evaluated qualitative and quantitative aspects
of nonspecific CTL activation in a viral model system. The
use of TCR transgenic mice provided a sensitive tool to
experimentally address several questions that escape detec-
tion in mice with a normal T cell repertoire. Although this
model situation may limit extrapolations of our results to
nontransgenic situations in some aspects, its high sensitivity
may also allow reevaluation of observations made under non-
transgenic conditions.
Our experiments are based on the observation that naive
TCR transgenic CD81 cytotoxic T cells specific for an
LCMV-derived peptide may differentiate into LCMV-spe-
cific cytolytic effector cells during infections with unrelated
pathogens in vivo or stimulation with allogenic spleen cells
in vitro. Since there is some uncertainty about the defini-
tion of naive cells, it may be important to state that we
consider naive cells to be from a 6–8-wk-old mouse that
has been kept under strict SPF conditions and that has not
undergone deliberate immunization. In a C57BL/6 mouse,
such naive cytotoxic T cells stain negative for CD69, but
z35% stain positive for CD44. LCMV-specific spleen cells
of SPF-kept TCR transgenic mice are also CD69 negative
and z9% stain positive for CD44. In TCR 3 RAG 2/2
mice, .98% of the TCR transgenic T cells are CD44 neg-
ative, which is similar to the findings of a recently pub-
lished report (29). In all of these mice, CD44 expression is
not associated with measurable cytolytic activity (Fig. 4),
which can be readily detected in spleen cells from nontrans-
genic virus-infected memory mice (Fig. 3). Furthermore, it
should be noted that the SPF maintenance conditions are
already quite artificial in terms of exposure to environmen-
tal antigens if compared to outbred mouse or human popu-
lations in a natural environment. For the experimental pur-
pose of this study, we, therefore, do not think that it would
be useful to define an even more naive state with the use of
cell surface markers. Finally, bystander activation also oc-
curs in CD44low cells, since it can also be demonstrated us-
ing CTL from TCR 3 RAG 2/2 mice, which display a
clear CD44 and CD69 negative phenotype (Fig. 6).
The finding that virus infections have the ability to poly-
clonally stimulate CTL has previously been reported for al-
loreactive CTL (7, 8) and for antigen-experienced virus-
specific CTL (2, 3, 30). Our studies in TCR transgenic mice
extend these findings to naive CTL specific for a viral anti-
gen and support the conclusion that the polyclonal stimula-
tion may comprise naive CTL clones of allo as well as con-
ventional specificities; however, they must be present at high
enough precursor frequency to be detectable in a func-
tional assay. Moreover and more importantly, we show
that this nonspecific activation of naive precursors does not
only elevate virus-specific CTLp, but that it is sufficient to
generate CTL that are cytolytically active. This is not only
demonstrated by their ability to lyse target cells in vitro, but
Table 1. Bystander Activation of CTL Is Not Sufficient to Cause Clinically Manifest Autoimmune Diabetes
Virus RIP gp/TCR mouse
Number of islets with
infiltrates .10 lymphocytes/islets monitored
Onset of diabetes
(day after infection)
d6 d15 d60
CD4 CD8 CD4 CD8 CD4 CD8
Vacc WR 1 1/9 1/6 3/6 3/6 .120
2 1/6 3/9 0/7 0/8 .120
3 0/12 0/13 5/11 6/12 .120
4 6/18 6/17 8/11 5/12 .120
Vacc LCMV GP 1 6/9 6/6 6
2 11/11 10/10 8/8 7/7 10
RIP-gp/TCR double transgenic mice (line 327) were infected with 2 3 106 PFU of vaccinia WR or recombinant vaccinia G2. 6, 15, and 60 d after
virus infection, mice were killed and immunohistochemical analysis of pancreata was performed with antibodies against CD4 and CD8. The islets of
Langerhans were considered infiltrated if .10 positive lymphocytes were detected per islet section. Nontransgenic C57BL/6 mice showed ,1
CD41 or CD81 cell per islet. Also indicated is the day when blood glucose levels reached levels .14 mM in four animals infected with vaccinia WR
and in two animals infected with vaccinia G2.1249 Ehl et al.
also by the finding that they can confer antiviral protection
in vivo. This shows that they home to infected tissue and
encounter infected cells in a complex environment where
there are many more uninfected than infected cells and where
they lyse these cells to efficiently stop further spread of virus.
What are the molecular mechanisms of this nonspecific
activation of cytotoxic T cells? This may be an important
question for understanding the pathogenesis of T cell–
mediated autoimmune disease and it has previously been
addressed in several experimental models. Three main
mechanisms have been discussed. The simplest explanation
may be that a given TCR not only recognizes its nominal
peptide, but can also interact with MHC molecules pre-
senting either homologous peptides derived from unrelated
proteins or peptides sharing crucial anchor positions (31,
32) with sufficient avidity for the T cell to be activated. Ex-
amples of such cross-reactivity are the basis of an extended
concept of molecular mimicry (12) and have also been im-
plied in the maintenance and modulation of T cell memory
(2, 3). To what extent these cross-reactivities defined in
vitro are of biological relevance in vivo is unknown (33).
Another possibility would be activation of a T cell of spec-
ificity X via a second TCR of specificity Y. Such dual re-
ceptor T cells have been described as occurring as a result
of incomplete allelic exclusion of the TCR-a gene locus
(16, 18). It was recently shown that cytolytic effector func-
tion for specificity X can be achieved after activation of a
CTL through specificity Y (13). Experiments using TCR 3
RAG 2/2 mice have suggested a role for a second TCR
in the generation of memory cells as defined by CD45 RB
expression in the absence of specific antigen priming (29).
However, for the interpretation of these results, it should
be kept in mind that TCR 3 RAG 2/2 mice do not only
lack the ability to rearrange and express endogenous TCR
a chains, but completely lack B or T cells of other specific-
ities. Experiments using RAG 2/2 mice are therefore un-
able to exclude that the induction of CD44 expression is a
consequence of cytokine-mediated bystander activation as
defined in this study. Furthermore, it is still an open ques-
tion whether these cells are of biological relevance in non-
transgenic mice in vivo, for example, whether activation
via an antiviral specificity can lead to autoimmune disease
via a second, antiself specificity.
Finally, rather than involving a single CTL reactive to
two different antigens, nonspecific activation of CTL may
represent bystander activation in a more strict definition of
the term; cytokines secreted by antigen-responsive cells at
infectious foci may directly stimulate surrounding CTL in
the absence of direct triggering of the T cell receptor. In
vitro studies have revealed that naive human CD41 T cells
can be activated by a combination of IL-2, TNF-a, and IL-6
(4). Furthermore, in vivo studies of antigen-experienced T
cells have shown that cytokines may break staphylococcal
enterotoxin B–induced T cell tolerance (34) and induce
nonspecific proliferation of CD44hi T cells (5). However,
(re-)activation requirements of antigen-experienced T cells
may be different from those of naive CTL. Also, the latter
studies have not addressed the question of whether the T cell
population induced to proliferate was also activated to pro-
vide effector function in vivo.
In the model situation presented in this study, naive T cells
differentiate into LCMV-specific cytolytic effector CTL af-
ter the infection of TCR transgenic mice with vaccinia vi-
rus or Listeria monocytogenes, both of which are strong in-
ducers of cytokine responses. Cold target competition
experiments and in vitro experiments with TCR 3 RAG
2/2 mice showed that this nonspecific CTL activation is
largely independent of a second TCR. Also, a cross-reac-
tive TCR appears an unlikely explanation, since it would
be surprising if stimuli as different as a virus, an intracellular
bacterium, and allogeneic spleen cells should all share cross-
reactivity with LCMV. In line with this argument, nonspe-
cific activation of a pure population of LCMV-specific CTL
in vitro was only possible in the presence of cells directly
responsive to the antigen. Moreover, incubation of TCR
transgenic T cells in IL-2–containing medium in the absence
of stimulating spleen cells, but obviously in the presence of
10% FCS and other potential foreign antigens, was suffi-
cient for the generation of LCMV-specific cytolytic effec-
tor CTL. Thus, while we cannot unequivocally analyze non-
specific CTL activation in vivo, our data obtained in vitro
suggest that TCR-independent activation mediated by cy-
tokines (but not type I IFN alone) is able to drive naive
CTLp into cytolytic effector CTL and may therefore be re-
sponsible for bystander activation.
Whatever the mechanism of nonspecific activation of
CTL, an important question is whether it is of significance
in vivo. Can bystander activation induced by a viral infec-
tion or cytokines functionally improve CTL memory to a
previously encountered unrelated virus? Former studies
have provided evidence that these nonspecific stimuli may
induce proliferation of memory CTL (5) and limiting dilu-
tion analysis has revealed that CTLp frequencies may be in-
fluenced by a factor of 2–4, rarely of 10 (2, 3). By assessing
cytolytic activity in vitro and antiviral protection in vivo, we
used a functional, rather than a numeric, definition of CTL
memory. By these criteria, we could not observe a significant
impact of a heterologous virus infection or interferon stim-
ulation on memory CTL. These results differ from those of
similar experiments published previously (2). The observed
decrease in ex vivo cytolytic activity of memory spleens
with increasing time after virus infection (compare Fig. 3, a
and c) might explain these differences; a fair comparison of
memory CTL activity is only possible at the same time after
the priming infection. Thus, our quantitative analysis re-
vealed that bystander activation is overall of low efficiency.
It is therefore not surprising that in LCMV-infected C57BL/6
memory mice, where CTLp frequencies are z1024–1023,
we found little, if any, consequence as assessed by cytotox-
icity assays.
Can bystander activation of potentially self-reactive CTL
cause autoimmune disease? We addressed this question in a
diabetes model where an LCMV antigen is expressed as a
transgene on pancreatic islet cells. Whereas autoimmune dia-
betes in these mice can be induced by infection with LCMV
(28), the introduction of a second LCMV-specific TCR trans-1250 Bystander Activation of Cytotoxic T Cells
gene amplifies the LCMV-specific CTLp about 10,000-
fold, and therefore increases the sensitivity of the model
significantly (22). Infection of these mice with an unrelated
third party virus generated significant LCMV-specific cyto-
toxicity. However, although some islet infiltration could be
demonstrated, the mice did not become diabetic. Why is
there insulitis but no progression to overt diabetes? Since cy-
tolytic effector function and homing properties of bystander-
activated CTL are indistinguishable from CTL activated via
their nominal antigen, it is unlikely to be due to a qualita-
tive difference in the CTL. It can be hypothesized that the
necessary LCMV-specific T cell help is not provided; al-
though infiltration of the islets with CD41 helper T cells was
observed, these cells may not be of the appropriate specific-
ity since the mice were primed with vaccinia virus. Lack of
concurrent bystander activation of antigen-specific T help
in addition to CTL could thus be a safeguard against non-
specifically induced autoimmune disease. More importantly,
previous studies have shown that induction of a threshold
number of self-reactive CTL is necessary for the induction
of diabetes in these mice (22). We therefore performed
quantitative experiments, which revealed that despite the
much higher precursor frequency of LCMV-specific CTLp,
the LCMV-specific cytotoxic activity per spleen was about
20-fold lower in TCR transgenic mice infected with the
nonspecific vaccinia virus when compared to nontrans-
genic mice infected with the specific LCMV. These quan-
titative differences may readily explain why the nonspecific
CTL activation did not suffice to cause clinically manifest
autoimmune diabetes.
With respect to the pathogenesis of autoimmune disease,
these data should be carefully interpreted within the limits
of the experimental model used in this study. Nevertheless,
since, due to the introduction of a transgenic TCR, a sensi-
tive, strongly reactive model is used that can readily reveal
antiviral effector funtion in vivo, a few aspects can be dis-
cussed in a broader context and may offer generalizable as-
pects. Besides negative selection, a relatively high level of
specificity (within the usual limits of biological systems) of
T cell–mediated immune responses is probably one of the
most important safeties against autoimmune disease. How-
ever, nonspecific activation by cytokines (and thus circum-
venting the specificity of the TCR) may occur, even to a
degree where cytolytic activity is demonstrable in vivo. For
this scenario, the present study emphazises an important ad-
ditional safety mechanism: that of a relatively high thresh-
old level of total induced and activated immune cells neces-
sary for biological effects (33).
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